Introduction
Although stem cell transplants have been used for over 40 years with demonstrated lifesaving capabilities for some blood diseases transplants have many associated risks, including possible induction of cancer (Cooley et al, 2000) , including skin cancer (Omland et al, 2016) , and aging of the tissue in which the implant occurs (Wood et al, 2016) . Many factors, often overlooked, must be considered when developing stem cell-based therapeutics, including something as fundamental as the choice of stem cell type where adipose mesenchymal stem cells have many advantages over bone marrow stem cells for therapeutic development . Here we performed a number of safety tests for a stem cell-based therapeutic comprised of the stem cell released molecules (secretome) from a combination of adipose derived mesenchymal stem cells (ADSCs) and fibroblasts (FBs), the combination of which has demonstrated efficacy in a number of conditions Maguire et al, 2019b) , and is conceptually based on developing a systems therapeutic (Maguire, 2014) for the physiological renormalization of tissue in various disease states or abnormal conditions . Using in vitro, in vivo, and skin sensitivity studies in humans, the stem cell therapeutic comprised of stem cell released molecules from ADSCs and FBs was shown to have an excellent safety profile when tested for in vitro and in vivo toxicity, the Ames mutagenicity assay, in vivo tumorigenesis, in vivo inflammation, ocular histology, and a human skin patch test for irritation and allergic reaction.
Methods
Stem cell culture procedures have been described previously .
Briefly, a proprietary collection of stem cell lines derived from human skin were cultured using no penicillin/streptomycin under hypoxic conditions. When cultures reached confluence, they were passaged for a limited number of times before disuse. Total conditioned medium from the multiple cell types, containing a soluble fraction and an exosome fraction, was harvested at each passage and the passages combined into one batch for product development. Parts of our stem cell technology used here are covered by US patents: 9545370; 9446075; 20140205563; 20130302273.
Safety Studies, HRIPT and Canine RIPT
The Human Repeat Insult Patch Test (McNamee et al, 2008) was used to assess primary and accumulative irritation, and/or allergic contact sensitization, in human subjects, male and female, between the ages of 18 and 66. All subjects were free of skin disease, and were prohibited from using topical or systemic antihistamines and steroids beginning seven days prior to the onset and throughout the duration of the study. Measurements were performed by a trained rater technician. For the induction phase of the study, the patches. 0.1 g of the combinatorial secretome per 1X1 inch square Webril dressing, were applied 3 times weekly for 3 weeks for a total of 9 applications. The patches were removed 48 hours after application and evaluated before the a fresh patch was reapplied to the same area. For the challenge phase of the study, two weeks after the final induction phase patch was applied, an adjacent, virgin area of skin then received a fresh patch and was evaluated at 24 and 72 hours following application of the patch. Ratings were scored using the following table: For the canine RIPT study, 27 qualified subjects absent of skin disease or irritation and no use of medications, male and female, ranging from age 2 to 7 years old were studied. S2RM was applied to the belly of the dog, held for two minutes to allow the S2RM to absorb into the skin, and no patch applied. The rater was a practicing veterinarian, who used the same rater scale that was used in the HIRPT. Photos were taken following each application that was done 3 times weekly for three weeks. All 27 dogs finished the study.
Oral Toxicity Studies
This toxicity study used 3 groups of 3 male and 3 female Sprague-Dawley rats (18 total). Once-daily oral (gavage) administration was as follows: Group 1 was administered the vehicle only once daily at 4.4 mL/kg/dose for 28 consecutive days.
Group 2 was administered S2RM once daily at 0.44 mL/kg/dose for 28 consecutive days. Group 3 was administered S2RM once daily at 4.4 mL/kg/dose for 28 consecutive days. As a biomarker for a possible inflammatory response to the S2RM administration, all rats were subjected to blood collection (Red-Top) for ELISA testing of the proinflammatory cytokines IL-10, and IL-31, measured prior to the first dose (Day 1) and on the day following the last dose (Day 29).
Results

Batch Reproducibility -Total protein
The method of Bradford was used in all protein determinations (Ernst and Zor, 2010).
The Bradford protein assay is a spectroscopic analytical procedure used to measure the concentration of protein in a solution. Samples, performed in duplicate, from a total of 15 batches of S2RM were analyzed. The variation between duplicates in all cases was less than 10%. Five samples of different S2RM batches, and 5 samples of the individual batches of SRM from the individual cell lines that make-up the S2RM, were analyzed for total protein. All samples were taken from frozen aliquots of batches previously used to make skin care products with demonstrated efficacy. All batches produced at least 500 ug/ml of total protein, with a high value in one batch of 630 ug/ml. The mean value of all batches was 554 ug/ml. The variability in all the batches was 20% or less. With the exception of one batch displaying a high protein count (630ug/ml), the rest of the batches had a variability of 12% or less.
Skin Safety Testing, Irritation
Ninety-one (91) qualified subjects, male and female, ranging in age from 18 to 66 years, were selected for this evaluation. Fifty (50) subjects completed the study. The remaining subjects discontinued their participation for various reasons, none of which were related to the application of the test material. Of the 50 subjects completing the study, all were rated at 0 during both the induction phase and the challenge phase, indicating that the S2RM induced no immediate or long term irritation, or allergic reaction. Because the S2RM is also intended for therapeutic development to treat companion animals, we tested for cross-species irritation in canines. Similar to that for humans, no irritation or allergic reaction was observed in the 27 canines as all scored "0" throughout the testing period.
Oral Administration Toxicity, Tumorigenesis, and Inflammation Results
No significant differences in organ weights were found in the male or female rats when compared to controls ( Figure 1A and B) . When compared to the control group, there were no biologically relevant changes from Day 1 to Day 29 for group average IL-10 or IL-31 in either SRM-treated group, suggesting that the S2RM did not induce an inflammatory reaction when administered orally. All tissues were also analyzed for tumor formation, and no tumors were found in any of the analyzed tissues (analyzed tissues are depicted in Figure 1 ) in any of the animals. As a general indicator of health, body weights were recorded prior to the first dose and weekly thereafter including the day of euthanasia ( Figure 1C ). When compared to the control group, there was mildly decreased body weight gain in high-dose (SRM at 4.4 mL/kg/dose) males and females over the course of the study. Body weight in the SRM low-dose group (Group 2, 0.44 mL/kg/dose) was comparable to the control group throughout the study in males and females. Therefore the general health and the appetite of the experimental animals was normal. of S2RM. No significant differences weights were observed for any of the organs, and none of the organs showed evidence of toxicity or tumorigenesis.
Analysis of Ocular Pathology and Tumorigeneicity Following Topical Application of S2RM to the Eye
Both eyes were recovered from all animals following seven consecutive days of twice daily administration of the S2RM as eye drops applied to the cornea. Eyes were submitted to Colorado Histo-Prep for histopathological evaluation by a board-certified veterinary pathologist who had no knowledge of which eyes had been treated. Six rabbits (New Zealand White) received the S2RM solution in one eye, and the other eye served as a control. One control rabbit receiving no S2RM in either eye was also was also used. The samples were trimmed, processed, embedded, sectioned, and stained.
Histopathology of the tissues was conducted on slides stained with hematoxylin and eosin with an emphasis on eye irritation and inflammation. No S2RM related lesions or tumors were observed in this study after 7 days of topical S2RM/Placebo treatment and prior to euthanasia. The eye globe sections were of very good quality and no differences in cornea morphology was detected in any specimen.
Ames Test
The Ames reverse mutation was used in four strains of Salmonella. Mutagens identified using the Ames test are usually carcinogens, given Ames showed that 90% of carcinogens are also mutagenic (McCann et al, 1975 ). In the four strains of bacteria tested (Figure 1) , the S2RM was shown to be non-mutagenic tested with S9 activation or without s9 activation. 
Cellular Cytotoxicity in a Mouse L929 Fibroblast Cell Line
Fibroblasts exists in most tissue compartments throughout the body, and particularly in the skin where the current S2RM technology has proven efficacious for a number of . We therefore tested the S2RM for potential cytotoxic effects in fibroblasts. Table 2 shows the data providing evidence that the S2RM has no cytotoxic effects in fibroblasts as measured by observing changes in cell structure or the number of cells in the culture. Table 2 . Using a mouse cell line L929, the S2RM conditioned media is shown to have no direct cytotoxic effects on the cells (fibroblasts).
Protein Misfolding Tests (Dermal Irritection® Assays System)
In this study Table 3 . S2RM did not induce any misfolding or structural changes in the collagen, keratin, and other dermal proteins.
Heavy Metals
Numerous products and procedures are involved in processing the stem cells for collection of their molecules, presenting a number of points were contamination may take place. We therefor tested for the presence of four common heavy metals in the S2RM end product used as the therapeutic. No significant level of heavy metals was present in the S2RM.
n, for ay he as Table 4 . Testing for the presence of four common heavy metals. None were present in significant, unsafe amounts.
Discussion
The results presented her for a combination therapeutic containing the stem cell While stem cell therapy is in a period of rapid advancement, the science of stem cell safety assessment must also evolve, not to hinder progress, rather to support, guide, and expedite the progress of patient treatment using stem cell-based technologies. The development of a rich safety data base is necessary to ensure that we can proceed with appropriate safeguards in place and allow that stem cell-based therapeutic approaches develop in a way that benefits society overall by using well supported, data driven risk versus reward analysis. These data presented here are one such needed set of safety data to evaluate the patient risk versus benefit ratio for stem cell therapeutics in general, and specifically for our combination of stem cell released molecules from adipose mesenchymal stem cells and fibroblasts.
